These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 2813332)

  • 1. Failure of a potent cholecystokinin antagonist to protect against diet-induced pancreatitis in mice.
    Ohshio G; Saluja A; Leli U; Sengupta A; Steer ML
    Pancreas; 1989; 4(6):739-43. PubMed ID: 2813332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of the cholecystokinin receptor antagonist L-364,718 on experimental pancreatitis in mice.
    Silverman M; Ilardi C; Bank S; Kranz V; Lendvai S
    Gastroenterology; 1989 Jan; 96(1):186-92. PubMed ID: 2462522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of the cholecystokinin receptor antagonist L-364,718 on pancreatitis induced by a deficient in choline and supplemented with ethionine (CDE) diet in the rat.
    Manso MA; Rodriguez AI; Garcia-Montero AC; De Dios I
    Arch Physiol Biochem; 1995 Aug; 103(4):410-5. PubMed ID: 8548474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cholecystokinin antagonist prevents hyperamylasemia and improves pancreatic exocrine function in cerulein-induced acute pancreatitis.
    Murayama KM; Drew JB; Nahrwold DL; Joehl RJ
    Pancreas; 1990 Jul; 5(4):439-44. PubMed ID: 1696383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Involvement of endogenous cholecystokinin in pancreatic regeneration after cerulein-induced acute pancreatitis.
    Jurkowska G; Grondin G; Morisset J
    Pancreas; 1992; 7(3):295-304. PubMed ID: 1594550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of the specific cholecystokinin antagonist L 364,718 in experimental acute pancreatitis in the rat.
    Sjövall S; Ahrén B; Stenram U
    Eur Surg Res; 1988; 20(5-6):325-9. PubMed ID: 2465158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beneficial effects of cholecystokinin-receptor blockade and inhibition of proteolytic enzyme activity in experimental acute hemorrhagic pancreatitis in mice. Evidence for cholecystokinin as a major factor in the development of acute pancreatitis.
    Niederau C; Liddle RA; Ferrell LD; Grendell JH
    J Clin Invest; 1986 Oct; 78(4):1056-63. PubMed ID: 2428840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cholecystokinin augmentation of 'surgical' pancreatitis. Benefits of receptor blockade.
    Modlin IM; Bilchik AJ; Zucker KA; Adrian TE; Sussman J; Graham SM
    Arch Surg; 1989 May; 124(5):574-8. PubMed ID: 2469410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of chronic administration of hydrocortisone on the induction and evolution of acute pancreatitis induced by cerulein.
    Pescador R; Manso MA; Rebollo AJ; de Dios I
    Pancreas; 1995 Aug; 11(2):165-72. PubMed ID: 7479674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Involvement of cholecystokinin receptors in the adverse effect of glucocorticoids on diet-induced necrotizing pancreatitis.
    Gomez G; Townsend CM; Green D; Rajaraman S; Uchida T; Thompson JC
    Surgery; 1989 Aug; 106(2):230-6; discussion 237-8. PubMed ID: 2474863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Action of CCK on CDE diet-induced acute pancreatitis in rats treated with hydrocortisone.
    Manso MA; Rebollo A; Pescador R; de Dios I
    Comp Biochem Physiol C Pharmacol Toxicol Endocrinol; 1995 Jun; 111(2):257-63. PubMed ID: 8521247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of short-term pancreatic duct obstruction in rats.
    Ohshio G; Saluja A; Steer ML
    Gastroenterology; 1991 Jan; 100(1):196-202. PubMed ID: 1700960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of cholecystokinin in the pathogenesis of acute pancreatitis in the isolated pancreas preparation.
    Nordback IH; Clemens JA; Cameron JL
    Surgery; 1991 Mar; 109(3 Pt 1):301-6. PubMed ID: 1705726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Octreotide and cholecystokinin antagonist reduce edema in obstruction-induced acute pancreatitis.
    Toriumi Y; Samuel I; Wilcockson DP; Turkelson CM; Solomon TE; Joehl RJ
    J Lab Clin Med; 1993 Oct; 122(4):450-4. PubMed ID: 8228560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cholecystokinin Receptor Antagonist Therapy Decreases Inflammation and Fibrosis in Chronic Pancreatitis.
    Nadella S; Ciofoaia V; Cao H; Kallakury B; Tucker RD; Smith JP
    Dig Dis Sci; 2020 May; 65(5):1376-1384. PubMed ID: 31598921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between severity, necrosis, and apoptosis in five models of experimental acute pancreatitis.
    Kaiser AM; Saluja AK; Sengupta A; Saluja M; Steer ML
    Am J Physiol; 1995 Nov; 269(5 Pt 1):C1295-304. PubMed ID: 7491921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological profile of T-0632, a novel potent and selective CCKA receptor antagonist, in vivo.
    Taniguchi H; Yazaki N; Yomota E; Shikano T; Endo T; Nagasaki M
    Eur J Pharmacol; 1996 Sep; 312(2):227-33. PubMed ID: 8894600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cholecystokinin receptor antagonist L-364,718 reduces taurocholate-induced pancreatitis in rats.
    Kim KH; Lee MG; Kim DG
    Int J Pancreatol; 1996 Dec; 20(3):205-11. PubMed ID: 9013282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cholecystokinin receptor antagonism by peptidergic and non-peptidergic agents in rat pancreas.
    Dembinski A; Jaworek J; Konturek PK; Konturek SJ; Warzecha Z
    J Physiol; 1989 Apr; 411():419-35. PubMed ID: 2614728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of a new cholecystokinin receptor antagonist loxiglumide on acute pancreatitis in two experimental animal models.
    Tani S; Okabayashi Y; Nakamura T; Fujii M; Itoh H; Otsuki M
    Pancreas; 1990 May; 5(3):284-90. PubMed ID: 2343042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.